India has initiated participation in a pivotal global clinical trial aimed at tackling neonatal sepsis, a significant cause of infant mortality. The first newborn was enrolled at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) in Puducherry. This move marks a crucial milestone as the country steps into the NeoSep1 trial, which is spearheaded by the Global Antibiotic Research and Development Partnership (GARDP).

Additionally, hospitals in Rohtak have commenced enrolling patients in the trial, with Mumbai expected to join shortly. India and Pakistan represent the inaugural Asian nations in this study, which aims to recruit 3,000 newborns across Asia and Africa by the year 2028. The trial has already commenced in regions like Ghana, Kenya, and South Africa, while countries such as Vietnam, Bangladesh, Malaysia, and Uganda are anticipated to participate shortly.

The Urgency of Addressing Neonatal Sepsis

Neonatal sepsis is a serious condition that affects infants aged 28 days or younger, leading to life-threatening responses to infections, primarily caused by bacterial pathogens. In India, sepsis is the second leading cause of neonatal mortality after factors such as prematurity and low birth weight, accounting for approximately 30 to 40 per cent of all newborn deaths. The rise of antimicrobial resistance (AMR) complicates treatment options, with drug-resistant infections posing a significant public health crisis.

Reportedly, AMR contributes to about 300,000 direct fatalities annually in India, with nearly 10 lakh deaths linked to drug-resistant infections. In light of these factors, the timing of India’s involvement in the NeoSep1 trial is particularly critical as newborn infections remain a leading cause of infant mortality and AMR complicates treatment options.

Every year, approximately three million newborns globally are afflicted with neonatal sepsis. This severe bloodstream infection can overwhelm a developing immune system within hours. While antibiotics have historically been the mainstay of treatment, the efficacy of many commonly used antibiotics has waned against resistant strains in hospital settings.

Innovative Approaches in the NeoSep1 Trial

The NeoSep1 trial distinguishes itself by evaluating and ranking multiple antibiotic combinations simultaneously, departing from the traditional method of comparing a singular treatment against another. This innovative personalised randomised trial design is intended to identify therapies that are both safe and effective, while also practical for hospitals encountering different resistance patterns.

The data generated from this trial could potentially influence both national and global guidelines for managing neonatal sepsis, particularly in low- and middle-income countries where access to advanced antibiotics remains restricted. The study builds on a previously completed phase in South Africa and Kenya in 2023, which established safe administration of the antibiotics fosfomycin and flomoxef for newborns when used alongside other treatments.

Dr Nishad Plakkal, principal investigator of the NeoSep1 trial in India and Head of Neonatology at JIPMER, expressed the urgency of identifying effective treatments. He highlighted the devastating reality that doctors frequently lose infants to sepsis due to limited treatment options. The trial aims to provide a beacon of hope by identifying optimal antibiotic therapies, essential for improving survival rates.

Sally Ellis, leader of GARDP’s Children’s Antibiotics Project, noted the growing challenge of antibiotic resistance faced by newborns. This trial aims to furnish neonatologists with evidence-based treatment protocols, subsequently bolstering the survival chances of infants suffering from sepsis. In a context where sepsis and antimicrobial resistance intersect with a considerable birth rate, this research could significantly inform the treatment landscape for neonatal medicine.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share